Coller B S
J Clin Invest. 1978 May;61(5):1168-75. doi: 10.1172/JCI109032.
Ristocetin will induce the agglutination of platelets in the presence of von Willebrand factor. In previous studies, an electrostatic mechanism was proposed for this phenomenon wherein first the platelet's surface charge is reduced by the binding of ristocetin and then the von Willebrand factor acts as a bridge between platelets. To test this hypothesis, the effects of ristocetin and von Willebrand factor, singly and together, on the electrophoretic mobility of normal, trypsinized, and Bernard-Soulier platelets was measured. Ristocetin alone, at concentrations of 0.5 mg/ml or more, produced a statistically significant reduction in the electrophoretic mobility of fresh or fixed platelets. Control experiments showed that the reduction was not due to changes in the ionic milieu of the solution. Therefore, the decrease in platelet mobility is evidence for binding of ristocetin to the platelet surface. Bernard-Soulier and trypsinized platelets also had reductions in mobility with ristocetin, suggesting that ristocetin binds to the platelet at sites other than the binding site for von Willebrand factor. The presence of plasma from a patient with von Willebrand's disease did not alter the reduction in mobility of normal platelets by ristocetin. However, the reduction was markedly enhanced in the presence of normal plasma. This enhancement did not occur with Bernard-Soulier platelets and was inhibited by anti-Factor VIII/von Willebrand factor antiserum or trypsinization of the platelets. Thus, the enhanced reduction appears to be associated with the binding of von Willebrand factor to the platelet surface. These studies indicate that platelets undergo two changes with ristocetin and von Willebrand factor, both of which facilitate agglutination: reduction in net surface charge and binding of von Willebrand factor, a large molecule which can serve as a bridge between platelets. In parallel studies, bovine von Willebrand factor, without ristocetin, agglutinated and reduced the electrophoretic mobility of normal but not Bernard-Soulier or trypsinized platelets; this indicates a similar mechanism of agglutination.
在血管性血友病因子存在的情况下,瑞斯托霉素会诱导血小板凝集。在先前的研究中,针对这一现象提出了一种静电机制,即首先瑞斯托霉素的结合降低了血小板的表面电荷,然后血管性血友病因子在血小板之间起到桥梁作用。为了验证这一假说,分别测量了瑞斯托霉素和血管性血友病因子单独及共同作用对正常血小板、胰蛋白酶处理的血小板和伯纳德 - 索利尔血小板电泳迁移率的影响。单独使用浓度为0.5毫克/毫升或更高的瑞斯托霉素,会使新鲜或固定血小板的电泳迁移率出现统计学上的显著降低。对照实验表明,这种降低并非由于溶液离子环境的变化。因此,血小板迁移率的降低证明了瑞斯托霉素与血小板表面的结合。伯纳德 - 索利尔血小板和胰蛋白酶处理的血小板在瑞斯托霉素作用下迁移率也降低,这表明瑞斯托霉素在血管性血友病因子结合位点以外的部位与血小板结合。血管性血友病患者的血浆存在时,并不会改变瑞斯托霉素对正常血小板迁移率的降低作用。然而,在正常血浆存在时,这种降低作用会显著增强。这种增强在伯纳德 - 索利尔血小板中未出现,并且会被抗因子VIII/血管性血友病因子抗血清或血小板的胰蛋白酶处理所抑制。因此,增强的降低作用似乎与血管性血友病因子与血小板表面的结合有关。这些研究表明,血小板在瑞斯托霉素和血管性血友病因子作用下会发生两种变化,这两种变化均有助于凝集:净表面电荷的减少以及血管性血友病因子的结合,血管性血友病因子是一种大分子,可在血小板之间起到桥梁作用。在平行研究中,不含瑞斯托霉素的牛血管性血友病因子会凝集正常血小板并降低其电泳迁移率,但对伯纳德 - 索利尔血小板或胰蛋白酶处理的血小板无此作用;这表明存在类似的凝集机制。